An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR- 20a-MICA/B axis.

In conclusion, 3'-O-acetylvitexin might act as a promising therapeutic agent for TNBC patients.
PMID: 31691589 [PubMed - as supplied by publisher]

Source: Natural Product Research - November 5, 2019 Category: Biochemistry Authors: Awad AR, Youness RA, Ibrahim M, Motaal AA, El-Askary HI, Assal RA, Gad MZ Tags: Nat Prod Res Source Type: research